BOZEMAN, Mont., May 18 /PRNewswire/ -- LigoCyte Pharmaceuticals announced today that Donald Beeman has joined the company as their new Chief Executive Officer. Most recently the President and Co-Founder of Topaz Pharmaceuticals LLC, Mr. Beeman has over 25 years experience in top executive positions in the pharmaceutical industry.
Before joining Topaz Pharmaceuticals, Mr. Beeman was the Vice President of U.S. Commercial Operations for Merck’s Vaccine Division. Mr. Beeman established a strong leadership reputation at Merck, having held executive positions in the Pharmaceutical and Marketing Divisions in both the United States and Australia. “I am impressed with what LigoCyte has accomplished and their strong vision for the future. I look forward to participating in the company’s growth,” said Mr. Beeman.
“We are very pleased to have Don join our company at this exciting time. As we prepare to take our Norovirus vaccine into the clinic, Don’s depth of expertise in all aspects of the pharmaceutical industry, especially the vaccine market, will allow LigoCyte to aggressively move forward as a clinical development company,” said Dr. Robert Goodwin, LigoCyte’s President and COO.
Mr. Beeman joins Dr. Goodwin, Dr. Robert Bargatze, LigoCyte’s Executive Vice President & CSO, and Dr. Charles Richardson, LigoCyte’s Executive Vice President of Research & Development, in leading the company into its first human clinical phase I trial.
About LigoCyte:
LigoCyte, established in 1998, is breaking new ground in the treatment of inflammatory and infectious diseases. The company has produced a number of novel drug compounds that modify immune responses by focusing on cell binding interactions and their role in the immune system. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry. For additional information on LigoCyte, please visit www.ligocyte.com.
About LigoCyte’s Norovirus Vaccine:
LigoCyte is developing a mucosal vaccine for the prevention of Norovirus infection in humans, a temporarily debilitating illness that afflicts nearly 23 million Americans annually. LigoCyte’s program is focused on an intranasally delivered, dry powder formulation. This approach induces a robust immune response at the critical site of infection, the gastrointestinal epithelium, and offers a shelf-stable formulation and simple, pain-free administration. For additional information on LigoCyte’s Norovirus vaccine, please visit http://www.ligocyte.com/pdf/norovirus.pdf.
Binding Science. Better Medicine.
Source: LigoCyte Pharmaceuticals, Inc.
